![](https://monteverdelaw.com/wp-content/uploads/case-logo/cymabay-therapeutics-inc.jpg)
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), relating to its proposed sale to Gilead Sciences, Inc. Under the terms of the agreement, CBAY shareholders will receive $32.50 in cash per share they own.
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), relating to its proposed sale to Gilead Sciences, Inc. Under the terms of the agreement, CBAY shareholders will receive $32.50 in cash per share they own.